

S5 Table. Characteristics of patients with and without statin exposure before the diagnosis of ER-negative breast cancer

	No statin (n=1,837)	Patients with statin exposure (n=294)	Total (n=2131)	p-value
Histologic type				
IDC	1,574 (85.68)	238 (80.95)	1,812 (85.03)	0.053 ^{a)}
ILC	20 (1.09)	2 (0.68)	22 (1.03)	
Others	243 (13.23)	54 (18.37)	297 (13.94)	
Stage: T				
T0	10 (0.54)	2 (0.68)	12 (0.56)	0.030 ^{a)}
T1	706 (38.23)	97 (32.99)	803 (37.68)	
T2	808 (43.98)	140 (47.62)	948 (44.49)	
T3	120 (6.53)	18 (6.12)	138 (6.48)	
T4	50 (2.72)	2 (0.68)	52 (2.44)	
Tis	143 (7.78)	35 (11.90)	178 (8.35)	
Stage: N				
N0	1,147 (62.44)	198 (67.35)	1,345 (63.12)	0.344 ^{a)}
N1	392 (21.34)	53 (18.03)	445 (20.88)	
N2	179 (9.74)	23 (7.82)	202 (9.48)	
N3	119 (6.48)	20 (6.80)	139 (6.52)	
Stage: M				
M0	1,815 (98.80)	291 (98.98)	2,106 (98.83)	> 0.999 ^{b)}
M1	22 (1.20)	3 (1.02)	25 (1.17)	
PR				
Negative	1,749 (95.21)	291 (98.98)	2,040 (95.73)	0.003 ^{a)}
Positive	88 (4.79)	3 (1.02)	91 (4.27)	
HER2				
Negative	764 (52.84)	114 (50.00)	878 (52.45)	0.426 ^{a)}
Positive	682 (47.16)	114 (50.00)	796 (47.55)	
Age at diagnosis (yr)				

< 40	318 (17.31)	0	318 (14.92)	< 0.001 ^{a)}
≥ 40 and < 50	545 (29.67)	23 (7.82)	568 (26.65)	
≥ 50	974 (53.02)	271 (92.18)	1245 (58.42)	
CCI				
Mean ± SD	4.16±1.99	5.07±2.30	4.29±2.06	< 0.001 ^{c)}
Median (min-max)	4 (0-16)	5 (0-12)	4 (0-16)	

Values are presented as number (%). CCI, Charlson comorbidity index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; M, metastasis; N, node; PR, progesterone receptor; SD, standard deviation; T, tumor. ^{a)}Chi-square test, ^{b)}Fisher exact test, ^{c)}Wilcoxon rank sum test.